The combination of VEGF inhibitor—bevacizumab with pembrolizumab has been shown safe and effective in ovarian cancer in phase 2 clinical study (Haunschild and Tewari et al. 2020; Zsiros et al. 2021). The gene discussed is VEGFA; the disease is ovarian carcinoma.